Royal Jelly as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Systemic Arterial Hypertension

ConditionsHypertension Cardiovascular Diseases (CVD)Inflammation

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-75

SponsorUniversidade Federal Fluminense

About this trial

The study aims to evaluate the effect of the royal jelly on inflammation and oxidative stress in participants with systemic arterial hypertension. A longitudinal double-blind randomized clinical trial will be carried out, involving hypertensive participants for two months.

Eligibility criteria

Qualifiers

Diagnosis of stage 1 hypertension

Regular treatment for more than 6 months

No changes in medication doses during the last 3 months

Disqualifiers

Autoimmune diseases

Infectious diseases

Diabetes

Chronic kidney disease

Trial design

Treatments tested in this trial

Royal Jelly
Placebo

Treatment groups

34 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Universidade Federal Fluminense

Lead sponsor

Source ClinicalTrials.gov